Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | ESR1 | P03372 | 4/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbon Tetrachloride SCHEMBL313349 | 0.91 | CYP3A4 (0.75) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL8581749 | 0.89 | TDP1 (0.63) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL11728684 | 0.88 | TDP1 (0.71) | CYP3A4TDP1ESR1ESR2TSHR | |
| Chloromethane SCHEMBL248726 | 0.88 | CYP3A4 (0.80) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL480830 | 0.87 | TDP1 (0.92) | CYP3A4TDP1ESR1ESR2TSHR | |
| Chloromethane SCHEMBL6903208 | 0.85 | CYP3A4 (0.75) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL1951204 | 0.84 | TDP1 (0.86) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL9420677 | 0.84 | TDP1 (0.86) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL561726 | 0.84 | TDP1 (0.86) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL3181354 | 0.84 | TDP1 (0.86) | CYP3A4TDP1ESR1ESR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0613480-A1 | PROCESS FOR THE PREPARATION OF CEPHEM DERIVATIVES | CHEIL FOODS & CHEMICALS, INC. (KR) | 1994-09-07 | — | — | EP | claimed |
| WO-1993010123-A1 | PROCESS FOR THE PREPARATION OF CEPHEM DERIVATIVES | CHEIL FOODS & CHEMICALS, INC. (KR) | 1993-05-27 | — | — | WO | claimed |
| EP-3030233-B1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10308645-B2 | Piperidine oxadiazole and thiadiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9828368-B2 | Oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170327490-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170313693-A1 | PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-02 | — | — | US | disclosed |
| US-20160176858-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | US | disclosed |
| EP-3030233-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2016-06-15 | — | — | EP | disclosed |
| WO-2016065584-A1 | PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| CN-1175600-A | Low-birefringent organic optical component and spirobiindan polymer | MITSUI TOATSU CHEMICALS (JP) | 1998-03-11 | — | — | CN | disclosed |
| EP-0826717-A1 | An organic optical component | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1998-03-04 | — | — | EP | disclosed |
| EP-0822545-A2 | Optical component and spirobiindan polymer therefor | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1998-02-04 | — | — | EP | disclosed |
| US-5686557-A | Polyamide resin which can be dissolved in alcohol solvent, composition thereof, and method of use thereof | TOMOEGAWA PAPER CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0776933-A1 | Polybutene-1 resin composition and a method of accelerating the crystal transformation | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 1997-06-04 | — | — | EP | disclosed |
| US-5491188-A | ADDING DIAMIDE COMPOUNDS AS NUCLEATING AGENT TO PROPYLENE HOMO-, CO- AND TERPOLYMERS; FILTRATION MEMBRANES, PRINTING SHEETS | NEW JAPAN CHEMICAL CO., LTD. (JP) | 1996-02-13 | — | — | US | disclosed |
| CN-1098725-A | Based on porous stretched article of acrylic resin and preparation method thereof | NEW JAPAN CHEM CO LTD (JP) | 1995-02-15 | — | — | CN | disclosed |
| EP-0632095-A2 | Porous stretched article of polypropylene-based resin and process for its preparation | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0557721-A2 | Crystalline polypropylene resin composition and amide compounds | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 1993-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017504-B2 | Piperidine isoxazole and isothiazole orexin receptor antagonists | HCRTR1, HCRTR2, OXTR | CYP3A4 2428/4885TDP1 4544/4885ESR1 749/4885 |
| US-20170313693-A1 | PIPERIDINE OXADIAZOLE AND THIADIAZOLE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | CYP3A4 3351/4885TDP1 4315/4885ESR1 1443/4885 |
| US-20160176858-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | CYP3A4 2494/4885TDP1 4575/4885ESR1 1204/4885 |
| US-20170327490-A1 | PIPERIDINE ISOXAZOLE AND ISOTHIAZOLE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | CYP3A4 3229/4885TDP1 4620/4885ESR1 944/4885 |
| US-10308645-B2 | Piperidine oxadiazole and thiadiazole orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | CYP3A4 3351/4885TDP1 4315/4885ESR1 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.